Inhaled cyclosporine aims to halt lung transplant rejection
NCT ID NCT03656926
First seen Feb 11, 2026 · Last updated Jun 23, 2026 · Updated 23 times
Summary
This Phase 3 trial tested whether adding inhaled liposomal cyclosporine A to standard care can improve lung function in 169 double lung transplant patients with chronic rejection. Participants inhaled the drug twice daily for 48 weeks. The main goal was to see if it slowed the decline in how much air they can exhale in one second (FEV1).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner Health
Phoenix, Arizona, 85013, United States
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Baylor University Medical Center
Dallas, Texas, 75246, United States
-
CHU Erasme
Brussels, Belgium
-
CHU Hopital Nord
Marseille, France
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Complexo Hospitalario de A Coruna
A Coruña, Spain
-
Copenhagen University Hospital
Copenhagen, Denmark
-
Duke University Medical Center
Durham, North Carolina, 27110, United States
-
Hannover Medical School
Hanover, Germany
-
Hospital Marques de Valdecilla
Santander, Spain
-
Hospital Puerta de Hierro
Madrid, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Reina Sofía
Córdoba, 14004, Spain
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, France
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Johns Hopkins University Hospital
Baltimore, Maryland, 21287, United States
-
LMU Klinikum Großhadern
Munich, Germany
-
Marie-Lannelongue
Le Plessis-Robinson, 92350, France
-
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224, United States
-
Medical University of Vienna
Vienna, Austria
-
Ohio State University Medical Center
Columbus, Ohio, 43210, United States
-
Rabin Medical Center
Petah Tikva, Israel
-
Royal Papworth Hospital
Cambridge, United Kingdom
-
Stanford University Hospital
Palo Alto, California, 94305, United States
-
Temple University Hospital
Philadelphia, Pennsylvania, 19140, United States
-
UC San Francisco
San Francisco, California, 94143, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
-
Universitair Ziekenhuis Leuven
Leuven, 3000, Belgium
-
University Hospital LA Fe
Valencia, Spain
-
University of Florida Medical Center
Gainesville, Florida, 32608, United States
-
University of Kentucky Albert B. Chandler Hospital
Lexington, Kentucky, 40508, United States
-
University of Manchester
Manchester, United Kingdom
-
University of Maryland
Baltimore, Maryland, 21201, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of South Florida
Tampa, Florida, 33606, United States
-
Washington University
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Liposomal cyclosporine A (inhaled)
What this could lead to
If it works, this could offer a new treatment option to slow lung function decline in double lung transplant patients with chronic rejection.
What could go wrong
This is a completed Phase 3 trial, but results may not show significant benefit over standard care. Inhaled cyclosporine may cause side effects like cough or infection.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.